ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Locally Advanced Ureter Urothelial Carcinoma
Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Locally Advanced Ureter Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BB |
Pembrolizumab Fred Hutchinson Cancer Center | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 3 | B |
Atezolizumab Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 20 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →